Thursday 16 October, 2025
Objectives: Acute inflammation, caused by infections or sepsis, can impact pharmacokinetics (PK). Here, we used a model-based analysis to evaluate…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine
Thursday 16 October, 2025
Introduction: In clinical and ambulatory care, drugs are often combined to improve the efficacy of the therapy. Especially the combination…
Read moreApplication of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection.
Thursday 16 October, 2025
Objectives: GLPG1205 is a novel, potent and selective antagonist of G protein-coupled receptor 84 (GPR84), activated by medium chain fatty…
Read morePhysiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers
Thursday 16 October, 2025
Introduction: Since nicotine is the pharmacologically active substance in tobacco responsible for addiction it also plays a distinctive role in…
Read morePhysiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab
Thursday 16 October, 2025
Introduction: The direct oral anticoagulant dabigatran is an important alternative to warfarin, as it has predictable pharmacokinetics (PK), anticoagulant effects…
Read morePeeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling
Thursday 16 October, 2025
Introduction: Grapefruit juice is listed by the FDA as strong inhibitor of cytochrome P450 (CYP) 3A4 [1] which metabolizes up…
Read morePhysiologically based pharmacokinetic modeling of amitriptyline and its active metabolite nortriptyline to investigate CYP2D6 and CYP2C19 mediated drug-drug and drug-gene interactions
Thursday 16 October, 2025
Introduction: The tricyclics amitriptyline and nortriptyline are both indicated for the treatment of several conditions, including depressive disorders or neuropathic…
Read moreParent-Metabolite Physiologically Based Pharmacokinetic Modeling of Mirtazapine during Drug-Drug- and Drug-Gene-Interactions
Thursday 16 October, 2025
Introduction: The racemate mirtazapine, used in treatment of major depressive disorders, is metabolized by several cytochrome P450 (CYP) enzymes, predominantly…
Read morePhysiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole
Thursday 16 October, 2025
Introduction: The antimycotic drug ketoconazole is well known for its strong drug-drug interaction (DDI) potential [1]. As a substrate and…
Read morePhysiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine
Thursday 16 October, 2025
Introduction: The intravenously administered cytotoxic drug 5-fluorouracil (5-FU) and its oral prodrug capecitabine (CCB) are used as first line agents…
Read more